Search for:

In brief

On 5 January 2024, the Italian Medicines Agency (AIFA)’s Resolution No. DG/526/2023 providing the list of medicines that must not be withdrawn from distribution and sale within the national territory, which, therefore, can’t be exported, was published in the Official Gazette.


Key takeaways

The Determination was issued pursuant to Article 1, paragraph 1, letter s), of the Legislative Decree No. 219/2006 which entrusts the AIFA with the power to temporarily block the export of medicinal products in order to prevent or limit shortages or unavailability, even temporary, on the market or in the absence of valid therapeutic alternatives.

Author

Roberto Cursano has been a lawyer in Baker McKenzie since September 2007. He focuses on healthcare law and compliance, and assists in tender procedures, the negotiation of public contracts and litigation before administrative courts. Mr. Cursano is a former administrative officer in the Italian Ministry of Health and helps clients work closely with the Italian Public Administration. He is admitted to the bar before the Italian Supreme Court and the Council of State. As well as training and tutoring in the master’s degree program on clinical trials of pharmaceutical products at the University of Rome Sapienza, Mr. Cursano regularly publishes articles and scientific contributions. He also frequently hosts and participates in seminars and presentations on pharmaceutical and administrative law matters.

Author

Riccardo Ovidi is an Associate in Baker McKenzie Rome office.

Author

Francesca R. Baratta is an Associate in Baker McKenzie Rome office.

Write A Comment